NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky announces it has commenced an investigation of SteadyMed Ltd. (“SteadyMed” or the “Company”) (NASDAQ:STDY) concerning possible violations of federal securities laws.
On August 31, 2017, SteadyMed revealed that it received a Refusal to File letter from the U.S. Food and Drug Administration ("FDA") regarding it New Drug Application ("NDA") for its product candidate Treyvent. Based on a preliminary review of the NDA, which was submitted in June 2017, the FDA determined that the application is not sufficiently complete to permit a substantive review. To obtain additional information, go to:
or contact Joseph E. Levi, Esq. either via email at email@example.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.